Patent law

Brooge Energy Ltd. Clients Renew 233,072 cbm of Storage Capacity at 70% Premium to Previous Pricing with Longer Term Fixed Income

Retrieved on: 
Tuesday, June 1, 2021
Legal costs, Maintenance fee, Patent law, CBM-FM, CBME-FM, Copyright renewal in the United States

The contract renewals consist of a total of 190,072 cbm signed with two clients on three-year terms each consisting of one year plus a two-year mutual renewal clause.

Key Points: 
  • The contract renewals consist of a total of 190,072 cbm signed with two clients on three-year terms each consisting of one year plus a two-year mutual renewal clause.
  • The remaining 43,000 cbm was renewed by a client for a three-year term consisting of six months plus six months, subject to mutual renewal for an additional two years.
  • Through the development of its Phase II and Phase III facilities, it is also building additional CPP storage capacity as well as crude oil storage capacity using similar technology.
  • Brooge Energy does not undertake any obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Poda Provides Update on its Patent Developments Over the Past Six Years

Retrieved on: 
Wednesday, May 26, 2021
Patent law, Poda, Patent application, Patent

VANCOUVER, BC, May 26, 2021 /PRNewswire/ - PODA LIFESTYLE AND WELLNESS LTD. ("Poda Lifestyle" or the "Company") (CSE: PODA) (FSE: 99L) is pleased to announce a comprehensive update on its patent developments that have been underway for the past six years.

Key Points: 
  • VANCOUVER, BC, May 26, 2021 /PRNewswire/ - PODA LIFESTYLE AND WELLNESS LTD. ("Poda Lifestyle" or the "Company") (CSE: PODA) (FSE: 99L) is pleased to announce a comprehensive update on its patent developments that have been underway for the past six years.
  • This patent provides PODA with protection based on the patent filings allowing PODA to be the only closed ended cigarette on the market.
  • In Summary PODA has filed numerous patents under PCT as follows:
    PCT WO 2018/165769 A1 Closed Bottom Vaporizer Pod Filed September 20, 2018.
  • Poda Lifestyle's HNB system is fully patented in Canada and is patent pending in 65 additional countries, covering over 70% of the global population.

Gateway Royalty Sounds Alarm on Ohio's H.B. No. 152

Retrieved on: 
Tuesday, May 25, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Metropolitan Borough of Oldham, Royalty

152, if enacted, "would fundamentally alter an unleased mineral owner's options in ways that would greatly benefit the Unit Operator to the detriment of the mineral owner,"says Chris Oldham, Gateway Royalty's president.

Key Points: 
  • 152, if enacted, "would fundamentally alter an unleased mineral owner's options in ways that would greatly benefit the Unit Operator to the detriment of the mineral owner,"says Chris Oldham, Gateway Royalty's president.
  • Based on some of the current operators' cost deductions, a 12.5% royalty under a net lease is the equivalent of a 6.25% royalty interest or less.
  • 152, Oldham says, "removes the ability of an unleased mineral owner to negotiate for a gross proceeds royalty and for a royalty percentage above 12.5%."
  • Oldham says that, for federal tax reporting purposes, Gateway uploads into Integra oil and gas revenue accounting software all 8/8ths information on the monthly royalty statements Gateway receives from each operator on the wells in which Gateway owns a royalty interest.

10x Genomics to Participate in Upcoming June Investor Conferences

Retrieved on: 
Monday, May 24, 2021
Monopoly, Financial markets, Patent law, 10x Genomics, United States securities law, U.S. Securities and Exchange Commission, Articles, Patent application, Patent, Regulation Fair Disclosure, Insider trading, Finance

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.

Key Points: 
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.
  • The companys integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.
  • The companys patent portfolio comprises 1,100 issued patents and patent applications.
  • 10x Genomics uses filings with the Securities and Exchange Commission, its website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

GTT Group Releases 1st Quarter Patent Transaction Market Report (PTMR)

Retrieved on: 
Friday, May 21, 2021
Intangible assets, Monopoly, Patent, Patent law, Outline of patents

b'PORTLAND, Ore., May 21, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, released its First Quarter 2021 Patent Transaction Market Report (PTMR) this morning.

Key Points: 
  • b'PORTLAND, Ore., May 21, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, released its First Quarter 2021 Patent Transaction Market Report (PTMR) this morning.
  • The report includes the Patent Market Index (PMI) and the Patent Licensing Index (PLI).\nThe first quarter PMI grew significantly, ultimately reaching a four-year peak.
  • The quarterly report also provides insight regarding recent filing trends in emerging and disruptive technology areas.\nThe Patent Market Index (PMI) tracks patent transaction activity and is reported quarterly in the Patent Transaction Market Report (PTMR).
  • The Patent Licensing Index (PLI) tracks publicly traded patent licensing companies and is also reported quarterly in the PTMR.\nAbout Global Technology Transfer Group, Inc.\nGlobal Technology Transfer Group, Inc. is a patent transaction advisory & consultancy firm.

Patent for ColdZyme approved in Japan

Retrieved on: 
Friday, May 21, 2021
Intellectual property law, Countries, Government, European Patent Organisation, Patent law, Patent, European Patent Office, European Patent Convention, Term of patent, Outline of patents

b'STOCKHOLM, May 21, 2021 /PRNewswire/ -- The Japanese patent authority has granted Enzymatica\'s patent for the cod enzyme that is a key component of Enzymatica\'s cold spray ColdZyme for the Japanese market.

Key Points: 
  • b'STOCKHOLM, May 21, 2021 /PRNewswire/ -- The Japanese patent authority has granted Enzymatica\'s patent for the cod enzyme that is a key component of Enzymatica\'s cold spray ColdZyme for the Japanese market.
  • Corresponding patent was granted by the European Patent Office, EPO, in the spring of 2020.\nEnzymatica has developed an improved cod enzyme formulation for ColdZyme, for which new patent applications were globally filed in 2016.
  • The new patent prolongs the protection for ColdZyme and other Enzymatica products based on the same technology platform for another 15 years.
  • This is a major strengthening of the Enzymatica patent portfolio and represents a significant milestone for the continuous commercialization of the company\'s key products.\n"Having the new patent also granted in Japan, we will have another large market, besides Europe and Russia, that will provide ColdZyme with a long-term patent protection.

Ely Gold Royalties Announces Change to Board of Directors

Retrieved on: 
Wednesday, May 19, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Ely

b'Vancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Ely Gold Royalties Inc. (TSXV: ELY) (OTCQX: ELYGF) ("Ely Gold" or the "Company") has announced that effective May 18, 2021 Mr. Tom Wharton has stepped down from the Board of Directors of Ely Gold Royalties due to personal reasons.\nMr.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Ely Gold Royalties Inc. (TSXV: ELY) (OTCQX: ELYGF) ("Ely Gold" or the "Company") has announced that effective May 18, 2021 Mr. Tom Wharton has stepped down from the Board of Directors of Ely Gold Royalties due to personal reasons.\nMr.
  • The Board recognizes Mr. Wharton\'s valuable contributions during his tenure at Ely Gold and wish him the best in his future endeavours.\nAbout Ely Gold Royalties Inc.\nEly Gold Royalties Inc. is a Nevada focused gold royalty company.
  • Ely Gold also generates development royalties through property sales on projects that are located at or near producing mines.
  • Management believes that due to the Company\'s ability to locate and purchase third-party royalties, its strategy of organically creating royalties and its gold focus, Ely Gold offers shareholders a favourable leverage to gold prices and low-cost access to long-term gold royalties in safe mining jurisdictions.\n'

Island Pharmaceuticals granted key patent for ISLA-101 in the United States

Retrieved on: 
Wednesday, May 19, 2021
Monopoly, Patent law, Patent, Pharmaceutical industry in China

Island has licensed the IP portfolio, generated by Monash University.\nExecutive Chairman of Island, Dr Paul MacLeman commented, "The grant of the US patent is a significant development for Island Pharmaceuticals.

Key Points: 
  • Island has licensed the IP portfolio, generated by Monash University.\nExecutive Chairman of Island, Dr Paul MacLeman commented, "The grant of the US patent is a significant development for Island Pharmaceuticals.
  • Having an allowed patent that protects Island\'s lead program in this large market provides protection for the development of ISLA-101 and further underpins our ability to advance the program in the US a key target market.
  • Hundreds of cases per annum have been seen in recent years in FIFO workers in West Australian mines.
  • Dengue is endemic in much of Asia, the South Pacific, South America, Central America and Africa.

Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL

Retrieved on: 
Tuesday, May 18, 2021
Intellectual property law, Patent law, United States Patent and Trademark Office, Patent application, Patent, Term of patent

The allowed application, \xe2\x80\x9cManufacturing of Bupivacaine Multivesicular Liposomes\xe2\x80\x9d claims composition of EXPAREL prepared by the company\xe2\x80\x99s 200-liter commercial-scale manufacturing process.

Key Points: 
  • The allowed application, \xe2\x80\x9cManufacturing of Bupivacaine Multivesicular Liposomes\xe2\x80\x9d claims composition of EXPAREL prepared by the company\xe2\x80\x99s 200-liter commercial-scale manufacturing process.
  • A Notice of Allowance is issued after the USPTO determines that the prosecution on the merits of a patent has been completed.
  • The USPTO then grants the patent upon payment of the patent issuance fee.
  • \xe2\x80\x9cThe comprehensive nature of the allowed claims underscores the deep multivesicular liposome manufacturing expertise that Pacira has accumulated over more than 25 years.

Retractable Technologies, Inc. Reports $23.4 Million in Operating Income for First Quarter Of 2021

Retrieved on: 
Monday, May 17, 2021
General Health, Health, Medical Supplies, Other Health, Profit, Expense, Intellectual property law, Patent law, Royalty payment, New York Stock Exchange, Earnings before interest and taxes, Finance

b"Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $23.4 million in the first quarter of 2021, compared to operating income for the same period last year of $481 thousand.

Key Points: 
  • b"Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $23.4 million in the first quarter of 2021, compared to operating income for the same period last year of $481 thousand.
  • In comparison, the annual operating income for the prior two years was $24.1 million in 2020 and $3.0 million in 2019.
  • Domestic unit sales were 95.6% of total unit sales for the three months ended March 31, 2021.
  • Royalty expense increased 236.2% due to increased gross sales.\nAs of March 31, 2021, Retractable employed approximately 210 full-time, part-time, and temporary employees.